Characterizing vitamin B6 pathway dependency in acute myeloid leukemia

急性髓系白血病维生素 B6 通路依赖性的特征

• 批准号: 10567925
• 负责人: LINGBO ZHANG
• 金额: $ 43.92万
• 依托单位: COLD SPRING HARBOR LABORATORY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-01-05 至 2027-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10567925
• 关键词: Acute Myelocytic Leukemia; Affect; BCL1 Oncogene; Blast Cell; Blood Cells; Bone Marrow; CRISPR screen; Candidate Disease Gene; Cell Line; Cell Proliferation; Cells; Cessation of life; Combined Modality Therapy; Data; Dependence; Environmental Risk Factor; Enzymes; Exhibits; Genetic Engineering; Genomics; Goals; Growth; Hematologic Neoplasms; Hematopoietic Neoplasms; Hematopoietic stem cells; Immune; Impairment; In Vitro; Investigation; Leukemic Cell; Malignant - descriptor; Malignant Neoplasms; Medical; Metabolic; Metabolic Pathway; Metabolism; Molecular; Myelogenous; Normal Cell; Pathway interactions; Patients; Pattern; Persons; Pharmacology; Process; Production; Proliferating; Proteins; Reaction; Regulation; Research; Sampling; Specificity; Technology; Therapeutic; Therapeutic Effect; Toxic effect; Treatment Efficacy; Vitamin B6; Vitamins; Work; acute myeloid leukemia cell; acute toxicity; cancer cell; cancer therapy; chemotherapy; druggable target; extracellular; functional genomics; improved; in vivo; in vivo Model; inhibitor; innovation; leukemia; leukemia treatment; mouse model; new therapeutic target; novel; novel therapeutic intervention; older patient; patient derived xenograft model; peripheral blood; pharmacologic; rapid growth; single-cell RNA sequencing; synergism; therapeutic target; tumorigenesis

PROJECT SUMMARY/ABSTRACT Acute myeloid leukemia (AML) is one of the most devastating blood cancers, and it affects around one million people and results in 147,000 deaths per year worldwide. AML is characterized by the abnormal production of myeloid lineage of blood cells and the rapid growth of leukemia blasts in bone marrow and peripheral blood. AML is a very aggressive cancer, and it progresses rapidly and AML patients become fatal within weeks to months. Currently, therapeutic options for AML are very limited. Only about 35% of AML patients under 60 years-old and 10% over 60 years-old benefit from standard chemotherapy. Thus, there is an urgent and unmet medical need to develop new therapeutic approaches particularly combination therapies with advanced efficacy and reduced toxicity for AML patients. Our long-term goals of the proposed research are to study abnormal vitamin pathways as metabolic dependencies in AML, to investigate critical regulators of vitamin pathways in supporting AML cell aberrant proliferation, and to identify druggable therapeutic targets in AML. We have recently uncovered vitamin B6 pathway as a novel dependency in AML. Based on this finding, we hypothesize that vitamin B6 pathway is a specific anti-leukemia target and has promising therapeutic potential to treat AML. To assess the hypothesis, we have identified multiple key enzymes in vitamin B6 dependent metabolic pathways essential for AML cell, but not for normal bone marrow hematopoietic stem and progenitor cell and immune cell, proliferation. Depletion of these key enzymes exhibited robust inhibition on AML proliferation. We have also validated vitamin B6 pathway as a pharmacologically actionable pathway and showed that vitamin B6 pathway inhibitors exhibit promising therapeutic efficacy in multiple genetically engineered AML models in vivo. These robust preliminary data encourage us to pursue three Specific Aims to further characterize vitamin B6 pathway: 1) to characterize both upstream and downstream regulators of vitamin B6 pathway in AML; 2) to evaluate the synergy between vitamin B6 pathway and BCL-2 in AML therapeutics to further enhance its efficacy; and 3) to perform functional genomics screens to identify vitamin B6 pathway synergistic effectors in AML. We propose to study AML from the aspect of vitamin B6 pathway and metabolic programming, a process which is novel and essential for AML cell proliferation. The proposed research will be focusing on both mechanistic understanding and therapeutic targeting of vitamin B6 pathway in association with different synergistic effectors in AML. The major goals of this proposal are to identify the unique vitamin B6 upstream regulators and downstream effectors as well as its synergistic effectors to treat AML. The proposal is significant because it will not only uncover the underlying mechanism but also pinpoint therapeutic targets to synergistically enhance the anti-leukemia effects in AML.

项目总结/文摘